Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | PEPD | P12955 | 2/20 | 0.47 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8248348 | 1.00 | POLB (0.52) | POLBALDH1A1FKBP1ALMNARAB9A | |
| SCHEMBL5097555 | 0.95 | FKBP1A (0.56) | POLBALDH1A1FKBP1ALMNARAB9A | |
| SCHEMBL2770377 | 0.90 | FKBP1A (0.42) | POLBALDH1A1FKBP1ALMNARAB9A | |
| SCHEMBL7333530 | 0.85 | POLB (0.54) | POLBALDH1A1FKBP1ALMNARAB9A | |
| SCHEMBL4179454 | 0.85 | FKBP1A (0.55) | POLBALDH1A1FKBP1ALMNARAB9A | |
| SCHEMBL7333522 | 0.85 | POLB (0.54) | POLBALDH1A1FKBP1ALMNARAB9A | |
| SCHEMBL13662643 | 0.85 | FKBP1A (0.55) | POLBALDH1A1FKBP1ALMNARAB9A | |
| SCHEMBL23135776 | 0.83 | ALDH1A1 (0.54) | POLBALDH1A1FKBP1ALMNARAB9A | |
| SCHEMBL5491765 | 0.83 | LMNA (0.54) | POLBALDH1A1FKBP1ALMNARAB9A | |
| SCHEMBL683797 | 0.83 | POLB (0.52) | POLBALDH1A1FKBP1ALMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3110795-A1 | NOVEL ECONOMIC PROCESS FOR VILDAGLIPTIN | Hikal Limited (IN) | 2017-01-04 | — | — | EP | disclosed |
| WO-2015128718-A1 | NOVEL ECONOMIC PROCESS FOR VILDAGLIPTIN | HIKAL LIMITED (IN) | 2015-09-03 | — | — | WO | disclosed |
| EP-1343493-B1 | USE OF(-) (3-HALOMETHYLPHENOXY) (4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR TREATMENT OF INSULIN RESISTANCE, TYPE 2 DIABETES AND HYPERURICEMIA | METABOLEX INC (US) | 2012-10-31 | — | — | EP | disclosed |
| US-8288438-B2 | Methods for avoiding edema in the treatment or prevention of PPARγ-responsive diseases, including cancer | METABOLEX, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288438-B2 | Methods for avoiding edema in the treatment or prevention of PPARγ-responsive diseases, including cancer | METABOLEX, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20120220577-A1 | GLYCINE B ANTAGONISTS | MERZ PHARMA GMBH & CO KGAA | 2012-08-30 | — | — | US | disclosed |
| EP-2438037-A1 | GLYCINE B ANTAGONISTS | Merz Pharma GmbH & Co. KGaA (DE) | 2012-04-11 | — | — | EP | disclosed |
| WO-2010139481-A1 | GLYCINE B ANTAGONISTS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2010-12-09 | — | — | WO | disclosed |
| US-20080269189-A1 | Method for Avoiding Edema in the Treatment or Prevention of Ppary-Responsive Diseases, Including Cancer | DIATEX, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080269189-A1 | Method for Avoiding Edema in the Treatment or Prevention of Ppary-Responsive Diseases, Including Cancer | DIATEX, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080194646-A1 | Methods For Avoiding Edema in the Treatment of Metabolic, Inflammatory, and Cardiovascular Disorders | DIATEX, INC. | 2008-08-14 | — | — | US | disclosed |
| US-20080194646-A1 | Methods For Avoiding Edema in the Treatment of Metabolic, Inflammatory, and Cardiovascular Disorders | DIATEX, INC. | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269189-A1 | Method for Avoiding Edema in the Treatment or Prevention of Ppary-Responsive Diseases, Including Cancer | PPARG, PPARA, PPARD | POLB 1516/4885ALDH1A1 1316/4885FKBP1A 1774/4885 |
| US-20120220577-A1 | GLYCINE B ANTAGONISTS | GLRB, GRIN2B, GLRA2 | POLB 2948/4885ALDH1A1 3645/4885FKBP1A 406/4885 |
| US-20080194646-A1 | Methods For Avoiding Edema in the Treatment of Metabolic, Inflammatory, and Cardiovascular Disorders | PPARG, PPARA, PPARD | POLB 2499/4885ALDH1A1 336/4885FKBP1A 2373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.